Eukaryotic Initiation Factor (eIF)
Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.
Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.
Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.
All Product Categories
-
Eukaryotic Initiation Factor (eIF) Inhibitors
(78)
View all products
-
Eukaryotic Initiation Factor (eIF) Antagonist
(1)
View all products
-
Eukaryotic Initiation Factor (eIF) Activators
(34)
View all products
-
Eukaryotic Initiation Factor (eIF) Modulators
(13)
View all products
-
Eukaryotic Initiation Factor (eIF) Chemicals
(3)
View all products
-
Eukaryotic Initiation Factor (eIF) Degraders
(2)
View all products
-
Eukaryotic Initiation Factor (eIF) Control
(1)
View all products
-
Eukaryotic Initiation Factor (eIF) Ligands
(3)
View all products
-
Eukaryotic Initiation Factor (eIF) Related Products (145)
Related Products (145)
-
Antibodies (15)
-
Fosigotifator
0 ImagesCat. No.: HY-153399CAS No.: 2415715-84-1Synonyms: ABBV-CLS-7262Fosigotifator (ABBV-CLS-7262) is a brain penetrant, orally active EIF2b (eukaryotic initiation factor) activator. Fosigotifator stabilizes the elF2B complex and boosts the activity, including that of complexes carrying pathogenic vanishing white matter (VWM) mutations. Fosigotifator is an integrated stress response inhibitor (ISRI). Fosigotifator can be used for amyotrophic lateral sclerosis research.
-
CMLD012073
0 ImagesCat. No.: HY-129769CAS No.: 2368900-32-5CMLD012073 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012073 inhibits the growth of NIH/3T3 cells with an IC50 of 10 nM. CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).
-
CMLD012072
0 ImagesCat. No.: HY-129768CAS No.: 2368900-33-6CMLD012072 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012072 can induce RNA clamping of eIF4A1 and eIF4A2 and possess potent anti-neoplastic activity.
-
eIF4A3-IN-7
0 ImagesCat. No.: HY-145361CAS No.: 2374759-82-5eIF4A3-IN-7 is a potent inhibitor of eIF4A3. eIF4A3-IN-7 has the potential for researching cancer and other dysproliferative diseases (extracted from patent WO2019161345A1, Compound 8).
-
eIF4E/eIF4G PPI-IN-1
0 ImagesCat. No.: HY-176288eIF4E/eIF4G PPI-IN-1 is an eIF4E/eIF4G interaction inhibitor with a KD of 20.2 μM for eIF4E protein. eIF4E/eIF4G PPI-IN-1 plays an antitumor role in multiple modes of action including regulating the activity of eIF4E by inhibiting the Ras/MAPK/eIF4E signaling pathway, apoptosis and cell migration. eIF4E/eIF4G PPI-IN-1 suppresses the growth of HepG2 xenografts in nude mice and was relatively nontoxic to mice.
-
ISR activator 2
0 ImagesCat. No.: HY-179524CAS No.: 332874-88-1ISR activator 2 is a selective ISR activator. ISR activator 2 can preferentially activate the ISR through the binding of the cytosolic pattern recognition receptor RIG-I, which subsequently activates the heme-regulated inhibitor (HRI) ISR kinase independent of an interferon response. ISR activator 2 can be used for the study of pancreatic cancer.
-
PTC-IN-1
0 ImagesCat. No.: HY-186313CAS No.: 3079914-21-6PTC-IN-1 is a human ribosomal peptidyl transferase center (PTC) inhibitor. PTC-IN-1 forms stable interactions with 28S rRNA and undergoes steric-hindrance electrostatic interactions with nascent polypeptide chains, thereby inducing context-dependent translation arrest. PTC-IN-1 activates the ribotoxic stress response through phosphorylation of p46 and p54 JNK, triggers ribosome collisions, and activates the integrated stress response via phosphorylation of eIF2α. PTC-IN-1 inhibits the proliferation of cancer cells. PTC-IN-1 can be used in the research of triple-negative breast cancer, prostate cancer, colorectal cancer.
-
ATP-γ-S tetrasodium
0 ImagesCat. No.: HY-134361CAS No.: 88453-52-5ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis.
-
(S)-DMP2
0 ImagesCat. No.: HY-187368(S)-DMP2 is a benzoxaborole-derived photoaffinity probe that efficiently enriches eukaryotic translation initiation factor 4E (eIF4E) with stereoselectivity. (S)-DMP2 acts as a cap-binding competitive inhibitor that competes with the 7-methylguanosine cap of mRNA for binding at the cap-binding pocket of eIF4E, covalently modifies residues within this pocket, and impairs the cap-binding ability of eIF4E. (S)-DMP2 is applicable to research on eIF4E-related mechanisms and diseases.
-
1,3-Bis[3,5-bis(trifluoromethyl)phenyl]urea
![1,3-Bis[3,5-bis(trifluoromethyl)phenyl]urea](https://file.medchemexpress.com/product_pic/hy-w046841.gif "Click to View 1,3-Bis[3,5-bis(trifluoromethyl)phenyl]urea Product Detail")
0 ImagesCat. No.: HY-W046841CAS No.: 3824-74-6
-
eIF4E-IN-1
0 ImagesCat. No.: HY-145240CAS No.: 2573979-31-2eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y).
-
4-Hydroxybenzophenone-d4
0 ImagesCat. No.: HY-W014937SCAS No.: 93496-64-1Synonyms: 4HBP-d44-Hydroxybenzophenone-d4 (4HBP-d4) is the deuterated-labeled 4-Hydroxybenzophenone (HY-W014937). 4‑Hydroxybenzophenone (4HBP) is a major metabolite of Benzophenone (HY-Y0546) and is orally active. 4-Hydroxybenzophenone triggers endoplasmic reticulum stress and activates the PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1s pathways, and inhibits IκB translation. 4-Hydroxybenzophenone induces endoplasmic reticulum stress, unfolded protein response activation, protein homeostasis imbalance, protein aggregation, oxidative stress, ROS accumulation, mitochondrial membrane potential decrease, ATP depletion, and cytotoxicity. 4-Hydroxybenzophenone induces neural stem cell apoptosis (apoptosis) and affects neuronal differentiation. 4-Hydroxybenzophenone promotes malignant proliferation of hepatocellular carcinoma cells and xenograft tumor growth in nude mice. 4-Hydroxybenzophenone can be used in research related to neurodevelopmental toxicity and hepatocellular carcinoma.
-
Comtifator
0 ImagesCat. No.: HY-177074CAS No.: 2518151-57-8Synonyms: BMS-986419; EVT-8683; EOAI-4018683Comtifator (Example 77) is a modulator of the integrated stress response pathway. Comtifator can be studied in research for diseases associated with integrated stress response.
-
DL149
0 ImagesCat. No.: HY-183253DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors.
-
Cytisine-platinum(IV) prodrug-1
0 ImagesCat. No.: HY-182360Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer.
-
PRXS571
0 ImagesCat. No.: HY-158198CAS No.: 2396759-31-0PRXS571 is a potent modulator of the neuronal integrated stress response (ISR) and can be used in neural-related research.
-
ZNL-02-096
0 ImagesCat. No.: HY-208742CAS No.: 2414418-56-5ZNL-02-096 is a selective Wee1 PROTAC degrader. ZNL-02-096 binds to CRBN and Wee1 to form a ternary complex, inducing CRBN- and proteasome-dependent ubiquitination and proteasomal degradation of Wee1. ZNL-02-096 inhibits recombinant PLK1 with an IC50 of 102 nM, but does not induce its degradation in cells. ZNL-02-096 induces G2/M phase arrest, Apoptosis, transient integrated stress response, upregulation of ATF4, and phosphorylation of GCN2. ZNL-02-096 reduces Tyr15 phosphorylation of CDK1. ZNL-02-096 can be used in research related to ovarian cancer, acute lymphoblastic leukemia, triple-negative breast cancer, multiple myeloma, and pancreatic ductal adenocarcinoma.
-
EIF2AK4 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70712EIF2AK4 Recombinant Human Active Protein Kinase belongs to a family of kinases that regulate angiogenesis in response to cellular stress. EIF2AK4 Recombinant Human Active Protein Kinase can be used for the study of pulmonary capillary hemangiomatosis (PCH).
-
OICR-403184
0 ImagesCat. No.: HY-184599OICR-403184 is a selective RNA-dependent protein kinase (PKR) inhibitor with limited brain penetration, with an IC50 of 263 nM. OICR-403184 blocks the phosphorylation of eIF2α downstream of PKR. OICR-403184 is applicable to the research of inflammatory bowel disease.
